Discovery of Inhibitors of the Lipopolysaccharide Transporter MsbA: From a Screening Hit to Potent Wild-Type Gram-Negative Activity

Author:

Verma Vishal A.1ORCID,Wang Lan1,Labadie Sharada S.1,Liang Jun1ORCID,Sellers Benjamin D.1ORCID,Wang Jian2,Dong Liting2,Wang Qiuyue2,Zhang Shuang2,Xu Zhongya2,Zhang Yexia2,Niu Yanan2,Wang Xinxin2,Wai John2,Koehler Michael F. T.1,Hu Huiyong1,Alexander Mary Kate1,Nishiyama Mireille1,Miu Anh1,Xu Yiming1,Pang Jodie1,Katakam Anand K.1,Reichelt Michael1,Austin Cary D.1,Ho Hoangdung1,Payandeh Jian1,Koth Christopher M.1

Affiliation:

1. Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States

2. WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People’s Republic of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Reference48 articles.

1. Recent Progress in Natural-Product-Inspired Programs Aimed To Address Antibiotic Resistance and Tolerance

2. Strategies for Discovering New Antibiotics from Bacteria in the Post-Genomic Era

3. Review on Antimicrobial Resistance; HM Governement, 2016 https://amr-review.org/home.html.

4. Roser, M.; Ritchie, H. Cancer; Global Change Data Lab, 2019 https://ourworldindata.org/cancer

5. Murepavadin: a new antibiotic class in the pipeline

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3